# Biotech Daily Digest â€” 2026-01-03

**5 items from 2 sources**

## Summary by Source

- Fierce Biotech: 4 items
- Regeneron Press Releases: 1 item


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/nih-instability-grows-exit-neuro-director-half-institutes-under-interim-leadership" hreflang="en">NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership</a>](https://www.fiercebiotech.com/biotech/nih-instability-grows-exit-neuro-director-half-institutes-under-interim-leadership)**  
  _Jan 2, 2026 1:55pm_  
  The National Institutes of Health is adding another leader to its lengthy string of departures, this time in the form of National Institute of Neurological Disorders and Stroke (NINDS) director Walter Koroshetz, M.D.

- **[<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026" hreflang="en">Fierce Biotech Layoff Tracker 2026: Nido winds down</a>](https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026)**  
  _Dec 23, 2025 10:11am_  
  As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

- **[<a href="https://www.fiercebiotech.com/biotech/abbvie-gilead-gift-themselves-clinical-stage-cancer-drugs" hreflang="en">AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals</a>](https://www.fiercebiotech.com/biotech/abbvie-gilead-gift-themselves-clinical-stage-cancer-drugs)**  
  _Jan 2, 2026 9:04am_  
  AbbVie and Gilead each used the holiday season to reward their pipelines with a new clinical-stage cancer drug.

- **[<a href="https://www.fiercebiotech.com/biotech/neuro-biotech-nido-closes-after-phase-2-study-fails-move-needle-rare-disease" hreflang="en">Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease</a>](https://www.fiercebiotech.com/biotech/neuro-biotech-nido-closes-after-phase-2-study-fails-move-needle-rare-disease)**  
  _Jan 2, 2026 9:59am_  
  After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study.


## Regeneron Press Releases

- **[Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026](https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2025-financial-and)**  
  _Fri, 02 Jan 2026 16:05:00 -0500_  
  TARRYTOWN, N.Y. , Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026 , before the U.S. financial markets open.
